Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
Public ClinicalTrials.gov record NCT01178346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Health-Related Quality-of-Life and Health-Care Resource Utilization Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
Study identification
- NCT ID
- NCT01178346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Nabi Biopharmaceuticals
- Industry
- Enrollment
- 500 participants
Conditions and interventions
Conditions
Interventions
- NicVAX vaccine Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2010
- Primary completion
- Oct 31, 2011
- Completion
- Oct 31, 2011
- Last update posted
- May 8, 2012
2010 – 2011
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NicVAX Investigator | Tucson | Arizona | 85724 | — |
| NicVAX Investigator | Encino | California | 91316 | — |
| NicVAX Investigator | Los Alamitos | California | 90720 | — |
| NicVAX | Newport Beach | California | 92660 | — |
| NicVAX Investigator | San Diego | California | 92108 | — |
| NicVAX Investigator | Denver | Colorado | 80204 | — |
| NicVAX Investigator | Brooksville | Florida | 34601 | — |
| NicVAX Investigator | Orlando | Florida | 32806 | — |
| NicVAX Investigator | St. Petersburg | Florida | 33709 | — |
| NicVAX Investigator | Tampa | Florida | 33606 | — |
| NicVAX Investigator | Boise | Idaho | 83704 | — |
| NicVAX | Indianapolis | Indiana | 46202 | — |
| NicVAX Investigator | Metarie | Louisiana | 700006 | — |
| NicVAX Investigator | Baltimore | Maryland | 21224 | — |
| NicVAX Investigator | Minneapolis | Minnesota | 55414 | — |
| NicVAX Investigator | Rochester | Minnesota | 55905 | — |
| NicVAX Investigator | Omaha | Nebraska | 68134 | — |
| NicVAX Investigator | Buffalo | New York | 14263 | — |
| NicVAX Investigator | Cincinnati | Ohio | 45237 | — |
| NicVAX Investigator | Mt. Pleasant | South Carolina | 29464 | — |
| NicVAX Investigator | Nashville | Tennessee | 37203 | — |
| NicVAX Investigator | Salt Lake City | Utah | 84020 | — |
| NicVAX Investigator | Salt Lake City | Utah | 84107 | — |
| NicVAX Investigator | Seattle | Washington | 98104 | — |
| NicVAX Investigator | Madison | Wisconsin | 53711 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01178346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2012 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01178346 live on ClinicalTrials.gov.